Becton Dickinson & Co.‘s (NYSE:BDX) C.R. Bard (NYSE:BCR) and subsidiary Davol this week avoided a lawsuit over allegedly defective hernia meshes after an appellate panel reaffirmed a lower court’s dismissal.
The lower court had dismissed the suit on the grounds that the operating physician in the case was informed of risks associated with the mesh, eliminating the plaintiff’s argument that the company did not appropriately warn physicians on the issue.
The decision came from the US Court of Appeals for the Eleventh Circuit on Wednesday, with Judges Marcus, Anderson and Hull finding in their review that the physician had been appropriately informed of the defect.
“The learned intermediary doctrine provides that the manufacturer’s duty to warn runs to the physician, not directly to the patient. If the physician had independent knowledge of the risk that caused the plaintiff’s injuries – substantially the same knowledge as an adequate warning should have communicated – then the plaintiff cannot prevail on a failure-to-warn claim,” the Judges wrote, according to a court documents. “We agree with the district court that the physician who implanted the instant patch had such independent knowledge. With respect to the patch that was implanted in plaintiff, there is insufficient evidence that the ring in the patch buckled.”
In July 2011, Bard paid nearly $185 million to settle lawsuits against its Davol subsidiary over hernia repair products, pushing the company into the red during its second quarter of that yea
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.